VivoSeq
Oncology

Triple Negative Breast Neoplasms

8

Pipeline Programs↗

1

Active Trials↗

7

Companies Involved↗

Triple Negative Breast Neoplasms is an early-stage landscape with 8 programs across 7 companies. The most active players are Merck & Co., Novartis, Teva. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

3 programs

Phase 3Novartis logo

Novartis

1 program

Phase 3Teva logo

Teva

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3A

Avyxa

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 38

Sacituzumab Tirumotecan

Merck & Co.

Pembrolizumab

Merck & Co.

Rescue Medication

Merck & Co.

Paclitaxel

Teva

Nab-Paclitaxel

Bristol-Myers Squibb

Approved
No programs

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody114%Antibody–drug conjugate114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 78% of 9 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Terminated1 · 50%

Clinical Trials

Trial Activity

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06841354·1,000 enrolled
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Terminated·Novartis logoNovartis·Phase 3·NCT04251533·137 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)